{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:41:49Z","timestamp":1774330909233,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.euf.2019.08.012","type":"journal-article","created":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T17:57:58Z","timestamp":1567706278000},"page":"309-316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Prostate-specific Membrane Antigen Positron Emission Tomography\u2013detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation"],"prefix":"10.1016","volume":"7","author":[{"given":"Stephanie G.C.","family":"Kroeze","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Henkenberens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2091-3603","authenticated-orcid":false,"given":"Nina Sophie","family":"Schmidt-Hegemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco M.E.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5556-6069","authenticated-orcid":false,"given":"Simon","family":"Kirste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2202-0905","authenticated-orcid":false,"given":"Jessica","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8029-8692","authenticated-orcid":false,"given":"Irene A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorsten","family":"Derlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Bartenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Eiber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Mix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"la Foug\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"Belka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie E.","family":"Combs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca L.","family":"Grosu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6539-0682","authenticated-orcid":false,"given":"Arndt Christian","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7146-9071","authenticated-orcid":false,"given":"Matthias","family":"Guckenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2019.08.012_bib0005","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2014.03.011","article-title":"Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02\/AUO AP 09\/95 trial","volume":"66","author":"Wiegel","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2019.08.012_bib0010","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2967\/jnumed.117.197160","article-title":"The impact of 68Ga-PSMA PET\/CT on management intent in prostate cancer: results of an Australian prospective multicenter study","volume":"59","author":"Roach","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euf.2019.08.012_bib0015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13014-018-0977-2","article-title":"Impact of 68Ga-PSMA-PET imaging on target volume definition and guidelines in radiation oncology\u2014a patterns of failure analysis in patients with primary diagnosis of prostate cancer","volume":"13","author":"Schiller","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.euf.2019.08.012_bib0020","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cncr.31860","article-title":"Oligometastatic prostate cancer: reality or figment of imagination?","volume":"125","author":"Foster","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2019.08.012_bib0025","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2019.08.012_bib0030","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/MOU.0000000000000449","article-title":"Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology","volume":"27","author":"Joice","year":"2017","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.euf.2019.08.012_bib0035","unstructured":"Royal Marsden NHS Foundation Trust. Conventional care versus radioablation (stereotactic body radiotherapy) for extracranial oligometastases (CORE). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02759783."},{"key":"10.1016\/j.euf.2019.08.012_bib0040","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1002\/cam4.1707","article-title":"The efficacy of stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer","volume":"7","author":"Franzese","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.euf.2019.08.012_bib0045","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.eururo.2015.04.035","article-title":"Patterns of clinical recurrence of node-positive prostate cancer and impact on long-term survival","volume":"68","author":"Nini","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2019.08.012_bib0050","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1748-717X-9-135","article-title":"Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence","volume":"9","author":"Decaestecker","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.euf.2019.08.012_bib0055","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.eururo.2015.07.004","article-title":"Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis","volume":"69","author":"Ost","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2019.08.012_bib0060","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2019.08.012_bib0065","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.eururo.2018.06.004","article-title":"Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial","volume":"74","author":"Siva","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2019.08.012_bib0070","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2019.08.012_bib0075","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.juro.2013.05.032","article-title":"Adjuvant and salvage radiotherapy after prostatectomy: AUA\/ASTRO guideline","volume":"190","author":"Thompson","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2019.08.012_bib0080","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.eururo.2017.06.002","article-title":"Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017","volume":"73","author":"Gillessen","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2019.08.012_bib0085","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(16)00111-X","article-title":"Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial","volume":"17","author":"Carrie","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2019.08.012_bib0090","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation with or without antiandrogen therapy in recurrent prostate cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2019.08.012_bib0095","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/bjc.2017.103","article-title":"Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study","volume":"116","author":"Triggiani","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euf.2019.08.012_bib0100","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eururo.2014.10.018","article-title":"Patterns of declining use and the adverse effect of primary androgen deprivation on all-cause mortality in elderly men with prostate cancer","volume":"68","author":"Sammon","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2019.08.012_bib0105","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1002\/cncr.24283","article-title":"Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer","volume":"115","author":"Taylor","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2019.08.012_bib0110","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2019.08.012_bib0115","article-title":"Standard of care versus metastases-directed therapy for PET-detected nodal oligorecurrent prostate cancer following multimodality treatment: a multi-institutional case-control study","author":"Steuber","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2019.08.012_bib0120","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00259-007-0581-4","article-title":"The detection rate of [11C]choline-PET\/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer","volume":"35","author":"Krause","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euf.2019.08.012_bib0125","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(17)30426-6","article-title":"Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial","volume":"18","author":"Duchesne","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2019.08.012_bib0130","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00259-018-4203-0","article-title":"Clinical impact of 68Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction","volume":"46","author":"Muller","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euf.2019.08.012_bib0135","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2967\/jnumed.118.212563","article-title":"Outcome after PSMA PET\/CT based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a bi-institutional retrospective analysis","volume":"60","author":"Schmidt-Hegemann","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euf.2019.08.012_bib0140","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.eururo.2017.11.020","article-title":"Use of concomitant androgen deprivation therapy in patients treated with early salvage radiotherapy for biochemical recurrence after radical prostatectomy: long-term results from a large, multi-institutional series","volume":"73","author":"Gandaglia","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2019.08.012_bib0145","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ijrobp.2003.10.015","article-title":"Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?","volume":"59","author":"King","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euf.2019.08.012_bib0150","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1470-2045(16)00107-8","article-title":"Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial","volume":"17","author":"Duchesne","year":"2016","journal-title":"Lancet Oncol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456919302706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456919302706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:51:28Z","timestamp":1762498288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456919302706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S2405456919302706"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2019.08.012","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate-specific Membrane Antigen Positron Emission Tomography\u2013detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2019.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}